Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

被引:9
|
作者
Ladas, Ioannis D. [1 ]
Chatziralli, Irini P. [1 ]
Kotsolis, Athanasios I. [1 ]
Douvali, Maria [2 ]
Georgalas, Ilias [1 ]
Theodossiadis, Panagiotis G. [2 ]
Rouvas, Alexandros A. [2 ]
机构
[1] Univ Athens, Med Sch Athens, Dept Ophthalmol 1, Athens, Greece
[2] Univ Athens, Med Sch Athens, Dept Ophthalmol 2, Athens, Greece
关键词
Age-related macular degeneration; Extrafoveal choroidal neovascularization; Ranibizumab; Thermal laser; VERTEPORFIN PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS; JUXTAFOVEAL; MARINA;
D O I
10.1159/000337347
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: To compare the efficacy of thermal laser photocoagulation versus intravitreal ranibizumab for the treatment of extrafoveal classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We conducted a retrospective study on 24 eyes with extrafoveal classic CNV secondary to AMD, treated either with thermal laser photocoagulation (group 1) or with intravitreal ranibizumab (group 2). Visual acuity, number of injections/sessions and recurrence rate were assessed. Results: The mean follow-up time was 23.6 +/- 2.26 and 19.1 +/- 9.74 months for group 1 and 2, respectively. Mean best corrected visual acuity (BCVA) of groups 1 and 2 was 0.59 +/- 0.32 and 0.46 +/- 0.30 logMAR, respectively (p = 0.343). At the end of the follow-up, mean BCVA of group 1 was 0.92 +/- 0.35 and of group 20.16 +/- 0.12 logMAR and differed statistically compared to baseline (p = 0.02 and p = 0.006, respectively). There was a statistically significant difference between the two groups as far as BCVA at the end of the follow-up was concerned (p < 0.0001). The patients in group 1 received on average 1.38 sessions of thermal laser photocoagulation, while patients in group 2 received on average 4 injections of ranibizumab. The recurrence rate in the laser group was 84.6%, while in the ranibizumab group it was 18.2% (p < 0.001). Specifically, the mean time of recurrence in the laser group was 11.5 months, whereas in the ranibizumab group it was 18 months (p = 0.048). Conclusion: Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections. Laser photocoagulation treatment presented worsening in BCVA and high recurrence rate in our study with long-term follow-up. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:93 / 101
页数:9
相关论文
共 50 条
  • [31] Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population
    Raj Vardhan Azad
    Mansur Ali Khan
    Bhuvan Chanana
    Shorya Azad
    Japanese Journal of Ophthalmology, 2008, 52 : 52 - 56
  • [32] Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population
    Azad, Raj Vardhan
    Khan, Mansur Ali
    Chanana, Bhuvan
    Azad, Shorya
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2008, 52 (01) : 52 - 56
  • [33] Feeder vessel treatment of occult with no classic choroidal neovascularization in age-related macular degeneration
    Roh, ML
    Glaser, BM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U413 - U413
  • [34] Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
    Rishi, Pukhraj
    Kasinathan, Nachiappan
    Sahu, Chinmaya
    CLINICAL OPHTHALMOLOGY, 2011, 5 : 167 - 170
  • [35] Photodynamic therapy combined with intravitreal bevacizumab (avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration
    Lazic, Ratimir
    Gabric, Nikica
    Dekaris, Iva
    Gavric, Morena
    Bosnar, Damir
    COLLEGIUM ANTROPOLOGICUM, 2007, 31 : 71 - 75
  • [36] Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
    Han, So Young
    Bae, Jeong Hun
    Oh, Jaeryung
    Yu, Hyeong Gon
    Song, Su Jeong
    DIABETES & METABOLISM JOURNAL, 2015, 39 (01) : 46 - 50
  • [37] PERSISTENCE OF CHOROIDAL NEOVASCULARIZATION (CNV) IN AGE-RELATED MACULAR DEGENERATION (AMD) FOLLOWING PHOTOCOAGULATION TREATMENT
    MURPHY, RP
    HINER, CJ
    PAPPAS, SS
    THOMPSON, JT
    SJAARDA, RN
    GLASER, BM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1994, 35 (04) : 1564 - 1564
  • [38] Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration
    Gallego-Pinazo, Roberto
    Marina Suelves-Cogollos, Ana
    Frances-Munoz, Ester
    Maria Millan, J.
    Fernando Arevalo, J.
    Luis Mullor, J.
    Diaz-Llopis, Manuel
    CLINICAL OPHTHALMOLOGY, 2011, 5 : 161 - 165
  • [39] GRID LASER TREATMENT OF OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION
    PICCOLINO, FC
    GHIGLIONE, D
    ALLEGRI, P
    INTERNATIONAL OPHTHALMOLOGY, 1993, 17 (02) : 77 - 83
  • [40] Perifoveal laser treatment for subfoveal choroidal neovascularization in age-related macular degeneration
    Falcone, P
    Chaudhry, NA
    Grannum, E
    OPHTHALMIC SURGERY AND LASERS, 1998, 29 (11): : 933 - 934